<DOC>
	<DOCNO>NCT00323609</DOCNO>
	<brief_summary>Patients osteoporotic vertebral body compression fracture randomly assign treatment balloon kyphoplasty vertebroplasty . Over 2 year follow-up , back pain , back function , quality life , adverse event , subsequent fracture cumulative healthcare cost compare .</brief_summary>
	<brief_title>KAVIAR Study - Kyphoplasty And Vertebroplasty In Augmentation Restoration Vertebral Body Compression Fractures</brief_title>
	<detailed_description>Medtronic Spine LLC sponsor KAVIAR study , randomize clinical trial compare balloon kyphoplasty vertebroplasty treatment osteoporotic vertebral body compression fracture ( VCFs ) . Up 1,234 subject 75 study center one three VCFs VB morphology suitable balloon kyphoplasty vertebroplasty randomly assign receive one procedure . Study visit occur baseline , 30 day postoperatively , 3 , 12 24 month postoperatively . At visit , adverse event , back pain , back function quality life assess . In addition , 7-day phone call conduct , include assessment back pain , narcotic use adverse event . At baseline , pre-discharge , 3- , 12- 24-month visit , lateral spine x-ray take . The primary endpoint proportion patient one subsequent fracture 12 24 month , detect radiographically determine core radiology laboratory . Secondary clinical endpoint include change baseline back pain , back function quality life , adverse event . Secondary radiographic comparison include restoration maintenance VB height angulation , sagittal vertical axis , measure global sagittal balance . A postoperative CT scan evaluate detect cement extravasation examine relationship cement distribution clinical outcome . Another important feature study detail healthcare utilization data assessment . Combined cost methodology base Medicare cost data source , cumulative two-year healthcare cost related VCF estimate . Combined quality life measurement , cost analysis allow calculation relative cost-effectiveness balloon kyphoplasty vertebroplasty . Sample size base primary endpoint , proportion subsequent fracture 12 24 month .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Fractures , Compression</mesh_term>
	<criteria>Inclusion Criteria All subject must meet follow criterion enrol study : 1 . Age &gt; 21 2 . 1 3 target VCFs meeting follow criterion : 1 . Fracture due diagnose presumed underlying primary secondary osteoporosis 2 . All target VCFs T5 L5 3 . All target VCFs treat show either : . Height change : An acute ( &lt; 6 month ) change VB height morphology previous xray , CT MRI , height loss anterior , middle posterior portion VB consistent worsen 1 grade Genant criterion ( 17 ) , OR ii . Positive MRI bone scan : VB show hyperintense signal STIR sequence MRI target VB positive radionuclide bone scan 4 . All VCFs treat fracture age ( time pain onset evaluation Investigator ) 6 month less 5 . Back pain correlate location least one VCF 3 . Treatment target VCFs technically feasible clinically appropriate BOTH vertebroplasty balloon kyphoplasty . ( Team approach : Both vertebroplasty balloon kyphoplasty physician review radiographic study agree prior enrol subject study . ) 4 . Pretreatment back pain numerical rating scale ( NRS ) score &gt; 4 ( 010 scale ) 5 . Pretreatment Oswestry Disability Index &gt; 20 ( 0 100 scale ) 6 . Subject state availability study visit 7 . Subject able understand risk benefit participate study willing provide write informed consent 8 . Subject mental capacity comply protocol requirement 2year duration study Exclusion Criteria Subjects meet follow condition may enrol study : 1 . VB morphology configuration either balloon kyphoplasty OR vertebroplasty technically feasible target VCFs 2 . Fracture due highenergy trauma 3 . Suspected OR proven cancer inside index vertebral body . Note patient chemotherapyrelated osteoporosis may include . 4 . Disabling back pain due cause acute fracture ( e.g. , sacroiliac fracture , symptomatic degenerative disc disease , lumbar spinal stenosis ) 5 . Any painful VCF fracture age &gt; 6 month 6 . Any objective evidence neurologic compromise baseline 7 . Previous balloon kyphoplasty vertebroplasty VCF 8 . Spine stabilization beyond balloon kyphoplasty vertebroplasty require target VCFs 9 . Significant clinical comorbidity may potentially interfere longterm data collection followup ( e.g. , dementia , severe comorbid illness ) 10 . Preexisting condition contrary either balloon kyphoplasty vertebroplasty , : 1 . Irreversible coagulopathy bleed disorder . Note regard reversible coagulopathies : Subjects coumadin anticoagulant may participate . Investigators follow routine practice perioperative discontinuation reinitiation anticoagulant . 2 . Allergy device material ( e.g. , bone cement ) balloon kyphoplasty vertebroplasty . Note subject allergy iodinebased contrast , noniodine contrast solution may use . 3 . Any evidence VB systemic infection 11 . Pregnant childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Kyphoplasty</keyword>
	<keyword>Vertebroplasty</keyword>
	<keyword>Balloon Kyphoplasty</keyword>
	<keyword>Inflatable Bone Tamp</keyword>
	<keyword>Spine</keyword>
	<keyword>Back Pain</keyword>
	<keyword>Vertebral Compression Fracture</keyword>
	<keyword>Vertebral Body Compression Fracture</keyword>
</DOC>